semaglutide cardiovascular outcomes news today and in Patients with Type 2 Diabetes Summary of the main cardiovascular
Description
Starting July 1, 2026, the Centers for Medicare and Medicaid Services (CMS) will launch a new federal program that gives many Medicare beneficiaries access to GLP-1 medications for weight management for the first time
People are excited about its chance to get FDA approval soon
Some plans require 3-6 months of documented prior attempts
Emerging research shows that GLP-1 weight-loss drugs like Ozempic, Wegovy, and Mounjaro may distort PET-CT scan results by altering tissue uptake of radioactive tracers, an effect that could mask tumors or make healthy tissue appear diseased
CINCINNATI U.S
